supp.fit

Ginkgo Biloba: study protocols

116 study groups say how much Ginkgo Biloba participants took a day. These are the doses the studies gave. They are not a recommendation.

Ginkgo Biloba: what the research found →

Dose per serving from products

1,725 products in our catalogue print how much Ginkgo Biloba a serving holds.

Most common: 100 mg to 250 mg, 33% of 1,725 products.

Dose per servingProducts
5 mg or less
48
5 mg to 10 mg
69
10 mg to 25 mg
153
25 mg to 50 mg
386
50 mg to 100 mg
376
100 mg to 250 mg
567
250 mg to 500 mg
62
over 500 mg
64

Dose per serving from research

116 study groups in 97 studies say how much Ginkgo Biloba participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 100 mg to 250 mg, 70% of 116 study groups.

Daily doseStudy groups
50 mg or less
3
50 mg to 100 mg
15
100 mg to 250 mg
81
250 mg to 500 mg
11
500 mg to 1 g
5
over 1 g
1

Commonly used together

14 of 116 study groups took Ginkgo Biloba with something else. Shown: what 3 or more different studies gave.

What was given together, not what works together.

Taken withStudy groups
Panax Ginseng
4

116 study groups

Study
Analysing Time to Event Data in Dementia Prevention Trials: The Example of the GuidAge Study of EGb761
2015 · EGb761® group · Community-dwelling adults aged over 70 years without dementia, with spontaneous memory complaints
240 mg5 years1,406
Limited cognitive benefits in Stage +2 postmenopausal women after 6 weeks of treatment with Ginkgo biloba
2005 · Ginkgo group · Postmenopausal women aged 51–67 years
120 mg6 weeks45
Efficacy of EGb 761(®) and Betahistine in Treatment of Dizziness/Vertigo: A Randomized Double-Blind Controlled Trial
2026 · EGb 761® group · Adults aged 20 years and older, male and female, with dizziness/vertigo of unclear etiology lasting longer than 1 month
120 mg12 weeks43
Acute cognitive effects of standardised Ginkgo biloba extract complexed with phosphatidylserine
2007 · 120 mg GBE · healthy young participants
120 mg1 day28
Effect of Ginkgo biloba extract on preexisting visual field damage in normal tension glaucoma
2003 · Ginkgo biloba extract (GBE) treatment · Patients with bilateral visual field damage resulting from normal tension glaucoma
120 mg4 weeks27
Differential cognitive effects of Ginkgo biloba after acute and chronic treatment in healthy young volunteers
2005 · ginkgo, experiment 1 (acute) · Healthy university students; age range and sex not specified
120 mg1 day26
Ginseng and Ginkgo Biloba Effects on Cognition as Modulated by Cardiovascular Reactivity: A Randomised Trial
2016 · Ginkgo Biloba medium dose · Undergraduate volunteers, mean age 20.2 years, female and male, without the listed excluded conditions or regular ginkgo use
120 mg1 day24
Differential cognitive effects of Ginkgo biloba after acute and chronic treatment in healthy young volunteers
2005 · ginkgo, experiment 2 (chronic) · Healthy university students; age range and sex not specified
120 mg6 weeks20
A placebo-controlled study of extract of ginkgo biloba added to clozapine in patients with treatment-resistant schizophrenia
2008 · EGb · Patients with chronic, treatment-resistant schizophrenia maintained on optimal doses of clozapine; age and sex not reported
120 mg12 weeks20
Effects on cognition and mood in postmenopausal women of 1-week treatment with Ginkgo biloba
2003 · Ginkgo · Postmenopausal women aged 53–65 years
120 mg7 days15
A double-blind, placebo controlled study of Ginkgo biloba extract ('tanakan') in elderly outpatients with mild to moderate memory impairment
1991 · Ginkgo biloba extract group · Patients over age 50 with mild to moderate memory impairment
120 mg24 weeks12
The effects of acute doses of standardized Ginkgo biloba extract on memory and psychomotor performance in volunteers
1999 · GBE 120 mg mane · Volunteers aged 30–59 years without a stated condition
120 mg2 days—
A 26-week analysis of a double-blind, placebo-controlled trial of the ginkgo biloba extract EGb 761 in dementia
2000 · EGb 761 group · Patients with mild to severe Alzheimer's disease or multi-infarct dementia
120 mg52 weeks—
Effectiveness of oral Ginkgo biloba in treating limited, slowly spreading vitiligo
2003 · Group A · Patients with limited, slowly spreading vitiligo
120 mg——
Ginkgo biloba: no robust effect on cognitive abilities or mood in healthy young or older adults
2006 · Ginkgo group, older adults · Healthy adults aged 55–79 years
120 mg12 weeks—
Ginkgo biloba: no robust effect on cognitive abilities or mood in healthy young or older adults
2006 · Ginkgo group, young adults · Healthy adults aged 18–43 years
120 mg12 weeks—
A randomized, placebo-controlled trial of Ginkgo biloba L. in treatment of premenstrual syndrome
2009 · experiment group · Students with premenstrual syndrome (PMS)
120 mg——
Cognitive psychophysiology in nootropic drug research: effects of Ginkgo biloba on event-related potentials (P300) in age-associated memory impairment
1995 · Ginkobene group · Patients aged 51–79 years with age-associated memory impairment
120 mg57 days—
[Placebo-controlled double-blind study of the effectiveness of Ginkgo biloba special extract EGb 761 in trained patients with intermittent claudication]
1996 · Ginkgo biloba special extract EGb 761 group · Adults aged 47–82 with Fontaine stage IIb peripheral arterial occlusive disease and intermittent claudication
120 mg24 weeks—
A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group
1997 · EGb · Mildly to severely demented outpatients with Alzheimer disease or multi-infarct dementia
120 mg52 weeks—
Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial
2011 · EGb 761 · Outpatients with mild to moderate Alzheimer’s disease, vascular dementia, or mixed dementia, with neuropsychiatric features; age and sex not reported
240 mg24 weeks202
Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg
2012 · EGb 761 group · Patients with mild to moderate dementia (Alzheimer's disease or vascular dementia) associated with neuropsychiatric symptoms
240 mg24 weeks200
A double-blind, placebo-controlled, randomized trial of Ginkgo biloba extract EGb 761 in a sample of cognitively intact older adults: neuropsychological findings
2002 · Ginkgo biloba extract EGb 761 · Men and women aged 60 years and older who were cognitively intact, community-dwelling volunteers without a history of dementia or significant neurocognitive impairment
180 mg6 weeks131
Efficacy of Getong Tongluo Capsule () for Convalescent-Phase of Ischemic Stroke and Primary Hypertension: A Multicenter, Randomized, Double-Blind, Controlled Trial
2021 · EGB group · Patients with convalescent-phase ischemic stroke and primary hypertension
80 mg12 weeks120
Ginkgo biloba extract EGb 761(®) versus pentoxifylline in chronic tinnitus: a randomized, double-blind clinical trial
2018 · EGb 761 group · Men and women aged 30 years or older with subchronic or chronic tinnitus lasting at least 3 months
240 mg12 weeks100
Efficacy and Safety of SID142 in Patients With Peripheral Arterial Disease: A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group, Phase III Clinical Trial
2022 · SID142 group · Adults with peripheral arterial disease; age and sex not specified
160 mg12 weeks86
Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial
2011 · EGb-761 · Inpatients with DSM-IV-diagnosed schizophrenia and tardive dyskinesia
240 mg12 weeks78
[Ginkgo extract in impaired vision--treatment with special extract EGb 761 of impaired vision due to dry senile macular degeneration]
2002 · group I · Patients with impaired vision due to senile, dry macular degeneration; age and sex not specified
240 mg26 weeks50
[Ginkgo extract in impaired vision--treatment with special extract EGb 761 of impaired vision due to dry senile macular degeneration]
2002 · group II · Patients with impaired vision due to senile, dry macular degeneration; age and sex not specified
60 mg26 weeks49
Investigating the efficacy of Ginkgo biloba on the cognitive function of patients undergoing treatment with electric shock: a double-blind clinical trial
2022 · Intervention group · Adults aged 18–60 with schizophrenia, schizoaffective disorder, bipolar disorder, or major depressive disorder undergoing electroconvulsive therapy
200 mg—40
Comparison of two dosages of ginkgo biloba extract EGb 761 in patients with peripheral arterial occlusive disease Fontaine's stage IIb. A randomised, double-blind, multicentric clinical trial
1999 · higher dosage · Patients with peripheral arterial occlusive disease, Fontaine stage IIb; age and sex not reported
240 mg24 weeks36
[The effect of ginkgo biloba on healthy elderly subjects]
2003 · EGb 761 group · Healthy adults aged 50–65, both sexes, without age-related cognitive impairments
240 mg4 weeks34
Effects of Ginkgo biloba extract EGb 761® on cognitive control functions, mental activity of the prefrontal cortex and stress reactivity in elderly adults with subjective memory impairment - a randomized double-blind placebo-controlled trial
2016 · EGb 761® group · Adults aged 50–65, male and female, with subjective memory impairment and no dementia
240 mg8 weeks31
[Treatment of cognitive and non-cognitive symptoms in cerebrovascular disease]
2014 · EGb 761 · Patients with discirculatory encephalopathy and cognitive impairment; mean age 60.8 years; sex not specified
240 mg24 weeks30
[Therapeutic effect of ginkgo biloba extract on postoperative delirium in aged patients]
2018 · Group A (medication group) · Elderly patients with postoperative delirium after tumor surgery
240 mg—29
Evidence of the regulatory effect of Ginkgo biloba extract on skin blood flow and study of its effects on urinary metabolites in healthy humans
2004 · EGb 761 treatment · healthy middle-aged adults
240 mg3 weeks27
Ginkgo biloba special extract LI 1370 improves dual-task walking in patients with MCI: a randomised, double-blind, placebo-controlled exploratory study
2017 · GBE intervention group (IG) · Adults aged 50–85 years with mild cognitive impairment and associated dual-task-related gait impairment
240 mg26 weeks25
Ginseng and Ginkgo Biloba Effects on Cognition as Modulated by Cardiovascular Reactivity: A Randomised Trial
2016 · Ginkgo Biloba high dose · Undergraduate volunteers, mean age 20.2 years, female and male, without the listed excluded conditions or regular ginkgo use
240 mg1 day24
EGb 761 in control of acute mountain sickness and vascular reactivity to cold exposure
1996 · EGb 761 group · Subjects taking part in a Himalayan expedition, with no stated age or sex; prevention of acute mountain sickness during gradual exposure to moderate altitude
160 mg—22
Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: a randomized, placebo-controlled trial
2007 · Ginkgo biloba group · People with multiple sclerosis; age range and sex not reported
240 mg12 weeks20
Ginkgo biloba for the prevention of severe acute mountain sickness (AMS) starting one day before rapid ascent
2002 · ginkgo · Adults residing at sea level before rapid ascent to Mauna Kea, Hawaii (median age 28 years; range 22–53)
180 mg1 day12
Ginkgo biloba decreases acute mountain sickness in people ascending to high altitude at Ollagüe (3696 m) in northern Chile
2007 · G biloba · Participants residing at sea level with no previous high-altitude experience, ascending to 3696 m
160 mg4 days12
The effect of Ginkgo biloba on functional measures in multiple sclerosis: a pilot randomized controlled trial
2006 · Ginkgo group · People with multiple sclerosis; age range and sex not specified
240 mg4 weeks11
Clinical randomized trial study of hearing aids effectiveness in association with Ginkgo biloba extract (EGb 761) on tinnitus improvement
2020 · Group 1 (G1) · Adults over 18 years, male and female, with tinnitus for at least 3 months and sensorineural or mixed hearing loss
240 mg90 days11
Clinical randomized trial study of hearing aids effectiveness in association with Ginkgo biloba extract (EGb 761) on tinnitus improvement
2020 · Group 3 (G3) · Adults over 18 years, male and female, with tinnitus for at least 3 months and sensorineural or mixed hearing loss
240 mg90 days11
Effects of Six-Week Ginkgo biloba Supplementation on Aerobic Performance, Blood Pro/Antioxidant Balance, and Serum Brain-Derived Neurotrophic Factor in Physically Active Men
2017 · study group (EGb) · Physically active men aged 20–24 years, healthy and without a stated disease
80 mg6 weeks9
The effects of acute doses of standardized Ginkgo biloba extract on memory and psychomotor performance in volunteers
1999 · GBE 150 mg (50 mg t. d.s) · Volunteers aged 30–59 years without a stated condition
150 mg2 days—
The effects of acute doses of standardized Ginkgo biloba extract on memory and psychomotor performance in volunteers
1999 · GBE 240 mg mane · Volunteers aged 30–59 years without a stated condition
240 mg2 days—
An examination of the efficacy of Ginkgo biloba extract EGb761 on the neuropsychologic functioning of cognitively intact older adults
2000 · Ginkgo biloba extract EGb 761 group · Cognitively intact adults aged 55–86 years
180 mg6 weeks—
Effect of treatment with Ginkgo biloba extract EGb 761 (oral) on unilateral idiopathic sudden hearing loss in a prospective randomized double-blind study of 106 outpatients
2001 · 120 mg twice daily · Adults with unilateral idiopathic sudden sensorineural hearing loss
240 mg8 weeks—
The efficacy of Ginkgo special extract EGb 761 in patients with tinnitus
2002 · EGb 761 oral treatment · Patients with chronic tinnitus aurium
160 mg12 weeks—
Ginkgo biloba extract EGb 761 in dementia: intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial
2003 · EGb 761 group · Patients with mild-to-moderate pre-senile or senile primary degenerative dementia of the Alzheimer type or multi-infarct dementia
240 mg24 weeks—
Ginkgo biloba special extract EGb 761 in generalized anxiety disorder and adjustment disorder with anxious mood: a randomized, double-blind, placebo-controlled trial
2007 · low-dose EGb 761 group · Patients with generalized anxiety disorder or adjustment disorder with anxious mood
240 mg4 weeks—
Effects of Ginkgo biloba extract EGb 761 on neuropsychiatric symptoms of dementia: findings from a randomised controlled trial
2007 · EGb 761-treated patients · Patients with dementia and neuropsychiatric features, including probable or possible Alzheimer's disease or vascular dementia
240 mg22 weeks—
[Therapeutic follow-up using automatic perimetry in chronic cerebroretinal ischemia in elderly patients. Prospective double-blind study with graduated dose ginkgo biloba treatment (EGb 761)]
1991 · Group B · Elderly patients with chronic cerebroretinal ischemia; mean age 74.9 years
160 mg4 weeks—
[Therapeutic follow-up using automatic perimetry in chronic cerebroretinal ischemia in elderly patients. Prospective double-blind study with graduated dose ginkgo biloba treatment (EGb 761)]
1991 · Group A · Elderly patients with chronic cerebroretinal ischemia; mean age 74.9 years
80 mg4 weeks—
Efficacy and tolerability of Ginkgo biloba extract EGb 761 by type of dementia: analyses of a randomised controlled trial
2009 · EGb 761 · Patients aged 50 years or above with dementia and neuropsychiatric features; subgroups had Alzheimer's disease or probable vascular dementia
240 mg22 weeks—
Baseline neuropsychiatric symptoms are effect modifiers in Ginkgo biloba extract (EGb 761®) treatment of dementia with neuropsychiatric features. Retrospective data analyses of a randomized controlled trial
2010 · EGb 761® group · Outpatients with mild to moderate Alzheimer’s disease, vascular dementia, or Alzheimer’s disease with cerebrovascular disease, all with neuropsychiatric features; age and sex not reported
240 mg24 weeks—
Specific memory effects of Ginkgo biloba extract EGb 761 in middle-aged healthy volunteers
2011 · EGb 761 · Healthy adults aged 45–56 years
240 mg6 weeks—
Efficacy and tolerability of a once daily formulation of Ginkgo biloba extract EGb 761® in Alzheimer's disease and vascular dementia: results from a randomised controlled trial
2012 · EGb 761® treatment · Outpatients aged 50 years or older with mild to moderate dementia, including Alzheimer's disease or vascular dementia, and neuropsychiatric features
240 mg24 weeks—
[Cerebral insufficiency--treatment with Ginkgo-biloba extract. Time of onset of effect in a double-blind study with 60 inpatients]
1990 · Ginkgo-biloba group · Inpatients with cerebral insufficiency and leading symptom of depressive mood
160 mg6 weeks—
Brain-derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to Ginkgo biloba
2012 · EGb-761 treatment · Chinese patients with schizophrenia and tardive dyskinesia
240 mg12 weeks—
Efficacy and safety of Ginkgo biloba extract EGb 761 in mild cognitive impairment with neuropsychiatric symptoms: a randomized, placebo-controlled, double-blind, multi-center trial
2014 · EGb 761-treated group · Patients with mild cognitive impairment and a score of at least 6 on the 12-item Neuropsychiatric Inventory
240 mg24 weeks—
Ginkgo biloba in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. A randomized, placebo-controlled, trial
2015 · Ginkgo biloba group · Children and adolescents with ADHD receiving methylphenidate
80 mg6 weeks—
The Acute and Chronic Cognitive and Cerebral Blood Flow Effects of a Sideritis scardica (Greek Mountain Tea) Extract: A Double Blind, Randomized, Placebo Controlled, Parallel Groups Study in Healthy Humans
2018 · 240 mg Ginkgo biloba extract · Healthy older adults; mean age 60.3 years; men and women
240 mg4 weeks—
Ginkgo biloba for Tardive Dyskinesia and Plasma MnSOD Activity: Association with MnSOD Ala-9Val Variant: A Randomized, Double-blind Trial
2024 · EGb761 group · Han Chinese adults aged 25–75 with schizophrenia and tardive dyskinesia, on stable antipsychotic medication
240 mg12 weeks—
Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia
1996 · EGb 761 · Presenile and senile outpatients with mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia
240 mg24 weeks—
Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type
1997 · EGb 761 group · Outpatients with mild to moderate dementia of the Alzheimer type; age and sex not reported
240 mg90 days—
The efficacy and safety of Ginkgo biloba extract as an adjuvant in type 2 diabetes mellitus patients ineffectively managed with metformin: a double-blind, randomized, placebo-controlled trial
2018 · GKB group · Adults aged 25–65, both sexes, with type 2 diabetes inadequately controlled by metformin
120 mg90 days30
Reduction of rise in blood pressure and cortisol release during stress by Ginkgo biloba extract (EGb 761) in healthy volunteers
2002 · EGb 761 · Healthy young volunteers; men and women; no stated condition
120 mg1 day—
[Treatment of Early Diabetic Retinopathy by Liuwei Dihuang Pill Combined Ginkao Leaf Tablet]
2016 · treatment group · Adults with type 2 diabetes mellitus and early diabetic retinopathy
57.6 mg2 years70
Ginkgo biloba extract improved cognitive and neurological functions of acute ischaemic stroke: a randomised controlled trial
2017 · GBE group · Adults aged 18–80 with acute ischaemic stroke
450 mg180 days179
[Effects of Ginkgo biloba extract in improving episodic memory of patients with mild cognitive impairment: a randomized controlled trial]
2012 · Ginkgo biloba leaf tablet group (treatment group) · Generally healthy, ambulatory or ambulatory-aided adults aged 60–85 with amnestic mild cognitive impairment and a memory complaint
57.6 mg26 weeks60
[Ginkgo leaves tablet improved the memory quotient of patients with mild cognitive impairment: a clinical observation]
2014 · treatment group · Patients with mild cognitive impairment; age and sex not reported
57.6 mg1 year58
A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia
2001 · EGb plus haloperidol · Adults with chronic, treatment-resistant schizophrenia; age and sex not stated
360 mg12 weeks56
Effects of Ginkgo biloba on mental functioning in healthy volunteers
2003 · EGb 761-treatment group · Healthy volunteers aged 50–65 years without age-associated cognitive impairment
720 mg4 weeks34
Effect of Pushen capsule for treating vascular mild cognitive impairment: a pilot observational study
2019 · control group (Ginkgo biloba tablets) · Adults aged 18 years or older with vascular mild cognitive impairment following stroke or lacunar infarction
57.6 mg12 weeks32
Modulation of cognition and mood following administration of single doses of Ginkgo biloba, ginseng, and a ginkgo/ginseng combination to healthy young adults
2002 · Ginkgo biloba · Healthy young adult volunteers; age range and sex not stated
360 mg1 day20
Effect of two doses of ginkgo biloba extract (EGb 761) on the dual-coding test in elderly subjects
1993 · 320 mg Ginkgo biloba extract (EGb 761) · Elderly men and women, mean age 69.3 years, with slight age-related memory impairment
320 mg1 day18
Effect of two doses of ginkgo biloba extract (EGb 761) on the dual-coding test in elderly subjects
1993 · 600 mg Ginkgo biloba extract (EGb 761) · Elderly men and women, mean age 69.3 years, with slight age-related memory impairment
600 mg1 day18
The effects of acute doses of standardized Ginkgo biloba extract on memory and psychomotor performance in volunteers
1999 · GBE 300 mg (100 mg t.d.s.) · Volunteers aged 30–59 years without a stated condition
300 mg2 days—
Effect of treatment with Ginkgo biloba extract EGb 761 (oral) on unilateral idiopathic sudden hearing loss in a prospective randomized double-blind study of 106 outpatients
2001 · 12 mg twice daily · Adults with unilateral idiopathic sudden sensorineural hearing loss
24 mg8 weeks—
Ginkgo biloba special extract EGb 761 in generalized anxiety disorder and adjustment disorder with anxious mood: a randomized, double-blind, placebo-controlled trial
2007 · high-dose EGb 761 group · Patients with generalized anxiety disorder or adjustment disorder with anxious mood
480 mg4 weeks—
Effect of Western medicine therapy assisted by Ginkgo biloba tablet on vascular cognitive impairment of none dementia
2012 · combined treatment group · Patients with vascular cognitive impairment of no dementia (VCIND); age and sex not reported
57.6 mg90 days—
Comparison of integrated traditional Chinese and western medicine therapy on vascular cognitive impairment with no dementia
2015 · combined treatment group · People with vascular cognitive impairment with no dementia (age and sex not reported)
57.6 mg90 days—
Study of the antiischemic action of EGb 761 in the treatment of peripheral arterial occlusive disease by TcPo2 determination
1994 · EGb 761 group · Patients aged 44–73 with stage II claudicating atherosclerotic arterial occlusive disease
320 mg4 weeks—
[Therapeutic effect of shuxuening combining neuroleptics for the treatment of chronic schizophrenia--a double blind study]
1997 · SXN group · People with chronic schizophrenia; age and sex not reported
360 mg16 weeks—
A double-blind, randomized clinical trial of dietary supplementation on cognitive and immune functioning in healthy older adults
2014 · Ginkgo Synergy® plus Choline · Adults aged 60 years and older without cognitive impairment or specified major illnesses
200 mg26 weeks33
Effect of Memo®, a natural formula combination, on Mini-Mental State Examination scores in patients with mild cognitive impairment
2013 · Memo group · Men and women aged 50–80 years with mild cognitive impairment
120 mg4 weeks30
Acute cognitive effects of standardised Ginkgo biloba extract complexed with phosphatidylserine
2007 · 120 mg GBE complexed with phosphatidylserine (Virtiva) · healthy young participants
120 mg1 day28
Acute cognitive effects of standardised Ginkgo biloba extract complexed with phosphatidylserine
2007 · 120 mg GBE complexed with phosphatidylcholine · healthy young participants
120 mg1 day28
The effect of Sailuotong (SLT) on neurocognitive and cardiovascular function in healthy adults: a randomised, double-blind, placebo controlled crossover pilot trial
2016 · SLT · Healthy adults; 16 participants completed the crossover trial
54.5 mg7 days16
The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers
2000 · 160 mg b.i.d. dosing regimen · Healthy middle-aged volunteers
120 mg14 weeks—
The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers
2000 · 320 mg o.d. dosing regimen · Healthy middle-aged volunteers
60 mg14 weeks—
Acute, dose-dependent cognitive effects of Ginkgo biloba, Panax ginseng and their combination in healthy young volunteers: differential interactions with cognitive demand
2002 · Ginkgo-Ginseng combination, 320 mg · Healthy young adults, mean age 21 years
320 mg1 day—
Acute, dose-dependent cognitive effects of Ginkgo biloba, Panax ginseng and their combination in healthy young volunteers: differential interactions with cognitive demand
2002 · Ginkgo-Ginseng combination, 640 mg · Healthy young adults, mean age 21 years
640 mg1 day—
Acute, dose-dependent cognitive effects of Ginkgo biloba, Panax ginseng and their combination in healthy young volunteers: differential interactions with cognitive demand
2002 · Ginkgo-Ginseng combination, 960 mg · Healthy young adults, mean age 21 years
960 mg1 day—
A randomized, double-blind, placebo-controlled study of Cistanche tubulosa and Ginkgo biloba extracts for the improvement of cognitive function in middle-aged and elderly people
2024 · CG group · Chinese middle-aged and elderly people at risk of neurodegenerative diseases
27 mg90 days—
A double-blind, randomised cross-over study to evaluate the absorption of a commercially available Ginkgo biloba extract compared to the liposomal extract Ginkgosome
2022 · Ginkgosome™ group · Healthy males and females aged 18–40 years with a healthy BMI and no clinically significant medical conditions
120 mg1 day14
A double-blind, randomised cross-over study to evaluate the absorption of a commercially available Ginkgo biloba extract compared to the liposomal extract Ginkgosome
2022 · Standard group · Healthy males and females aged 18–40 years with a healthy BMI and no clinically significant medical conditions
120 mg1 day14
Investigating the Effects of a Multinutrient Supplement on Cognition, Mood and Biochemical Markers in Middle-Aged Adults with 'Optimal' and 'Sub-Optimal' Diets: A Randomized Double Blind Placebo Controlled Trial
2022 · active supplementation · Adults aged 40–65 years, healthy and without neurological, cognitive, mood or psychiatric disorders; participants had either an optimal or sub-optimal diet
6 g12 weeks70
The ingestion of Ginkgo biloba extract (EGb 761) inhibits arachidonic acid-mediated platelet aggregation and thromboxane B2 production in healthy volunteers
2004 · EGb 761 · Non-diabetic volunteers, mean age 39 ± 13 years; sex not reported
120 mg90 days12
Ginkgo biloba extract increases ocular blood flow velocity
1999 · Ginkgo biloba extract treatment · Healthy volunteers, 34 ± 3 years; 8 women and 3 men
120 mg2 days11
The effect of Ginkgo biloba extract on genotoxic damage in patients with differentiated thyroid carcinoma receiving thyroid remnant ablation with iodine-131
2012 · GBE · Patients aged 18–73 with differentiated thyroid carcinoma receiving iodine-131 thyroid remnant ablation
120 mg30 days10
Ticlopidine with Ginkgo Biloba extract: a feasible combination for patients with acute cerebral ischemia
2013 · ticlopidine plus Gingko Biloba extract (EGb) · Patients with acute cerebral ischemia
160 mg90 days43
Clinical and genomic safety of treatment with Ginkgo biloba L. leaf extract (IDN 5933/Ginkgoselect®Plus) in elderly: a randomised placebo-controlled clinical trial [GiBiEx]
2018 · IDN 5933 · Elderly nursing-home residents aged 65 years or older, with chronic conditions; men and women
240 mg26 weeks34
A new ginkgo fresh plant extract increases microcirculation and radical scavenging activity in elderly patients
2011 · ginkgo extract group · Elderly patients; sex and specific condition not stated
180 mg30 days16
Short-term effects of Ginkgo biloba extract on peripapillary retinal blood flow in normal tension glaucoma
2011 · GBE-treated study group · Adults aged 18–80 with normal tension glaucoma
160 mg4 weeks15
Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and Ginkgo biloba extracts in healthy subjects
2013 · Simvastatin co-treated with GBE · Healthy volunteers; age range and sex not reported
240 mg2 weeks14
Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba
2005 · Ginkgo biloba supplementation · Healthy elderly adults, 67 ± 5.2 years; 6 men and 6 women
240 mg4 weeks12
Pharmacokinetics and bioavailability of a Ginkgo biloba extract
2002 · 40 mg twice daily · 12 healthy volunteers; sex and age not reported
80 mg7 days—
Pharmacokinetics and bioavailability of a Ginkgo biloba extract
2002 · 80 mg once daily · 12 healthy volunteers; sex and age not reported
80 mg7 days—
[Effect of extract of ginkgo bilboa leaf on early diabetic nephropathy]
2005 · treated group · Patients with early diabetic nephropathy
28.8 mg90 days34
Ginkgo biloba extract (EGb 761) pretreatment limits free radical-induced oxidative stress in patients undergoing coronary bypass surgery
1997 · EGb 761 · Patients undergoing aortic valve replacement and coronary bypass surgery
320 mg5 days8
The effects of Ginkgo biloba extract added to haloperidol on peripheral T cell subsets in drug-free schizophrenia: a double-blind, placebo-controlled trial
2006 · EGb plus haloperidol · Adults with schizophrenia who were inpatients
360 mg12 weeks—
[Effect of combined therapy with hypha Cordyceps and ginkgo leaf tablet on micro-inflammation in patients undergoing maintenance hemodialysis]
2008 · treated group · Patients undergoing long-term maintenance hemodialysis; age and sex not reported
690 mg90 days33